Laura Khandagle, MD
Internal Medicine · Silver Spring, MDNPI 1235112905
Payments from drug & device makers
Across 244 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$709
- Lilly USA, LLC$598
- AstraZeneca$455
- Amgen$378
- Boehringer Ingelheim$265
- AbbVie$255
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,31099%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $709 |
| Lilly USA, LLC | 29 | $598 |
| AstraZeneca | 25 | $455 |
| Amgen(2 entities) | 38 | $378 |
| Boehringer Ingelheim | 11 | $265 |
| AbbVie(2 entities) | 13 | $255 |
| Pfizer | 13 | $219 |
| Astellas Pharma US Inc | 9 | $172 |
| Merck | 11 | $153 |
| Lundbeck LLC | 4 | $107 |
| Abbott | 5 | $104 |
| GSK | 5 | $101 |
| Johnson & Johnson | 5 | $97 |
| Novartis | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Kowa Pharmaceuticals America, Inc. | 4 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Exact Sciences | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Scilex Pharmaceuticals Inc. | 2 | $41 |
| Gilead | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| Dexcom, Inc. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Verona Pharma, Inc. | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
How this compares
$4,343 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 94 | $182,475 |
| OzempicSemaglutide | 84 | $173,676 |
| JardianceEmpagliflozin | 61 | $79,066 |
| RybelsusSemaglutide | 17 | $39,198 |
| EliquisApixaban | 31 | $38,582 |
| JanuviaSitagliptin Phosphate | 25 | $29,598 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $20,703 |
| EntrestoSacubitril/Valsartan | 17 | $18,131 |
| TradjentaLinagliptin | 16 | $14,141 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,243 |
| Rosuvastatin Calcium | 343 | $8,855 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $8,296 |
| Risedronate Sodium | 71 | $7,030 |
| Dexlansoprazole DrDexlansoprazole | 16 | $6,803 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $6,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $709 | $212,874101 claims |
| Lilly USA, LLCMounjaro | $598 | $182,47594 claims |
| Boehringer IngelheimJardiance, Tradjenta | $265 | $93,20677 claims |
| PfizerEliquis | $219 | $38,58231 claims |
| MerckJanuvia | $153 | $29,59825 claims |
| NovartisEntresto | $90 | $18,13117 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $101 | $17,53931 claims |
| AbbVieSynthroid | $255 | $3,77179 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $3,742317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Silver Spring
- Husna BakshSilver Spring$1.3M
- Kathryn KellySilver Spring$533K
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.